Euvolemia as a criterion of diuretic therapy efficacy in chronic heart failure: Literature review
https://doi.org/10.29001/2073-8552-2020-35-2-13-25
Abstract
Chronic heart failure (CHF) is a typical outcome for all pathological processes affecting the cardiovascular system and is diagnosed in 1–2% of the population in developed countries. The strategy for managing patients with CHF involves the prescription of diuretics for the relief of volume retention syndrome in addition to pathogenetic pharmacotherapy. Considering the confl icting data concerning the effects of diuretics on the long-term prognosis and clinical course of CHF, a strict approach to the analysis of risk/benefit ratio is necessary while choosing a specific diuretic and determining its optimal dose and duration of use. The article reviews state-of-theart literature on the assessment of hydration status in patients with CHF. The euvolemia state, in which the optimal volume of fl uid is achieved in the body of a patient with CHF is viewed from the perspective of evaluating the efficacy and relevance of diuretic therapy.
About the Authors
A. A. Garganeeva
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Head of the Department of Myocardial Pathology,
111a, Kievskaya str., Tomsk, 634012
E. A. Kuzheleva
Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences
Russian Federation
Russian Federation
Cand. Sci. (Med.), Research Scientist, Department of Myocardial Pathology,
111a, Kievskaya str., Tomsk, 634012
V. Yu. Mareev
Lomonosov Moscow State University
Russian Federation
Russian Federation
Dr. Sci. (Med.), Professor, Chief Research Scientist, Medical Scientific and Educational Center,
1, Leninskie Gory, Moscow, 119991
References
1. Mareev V.Y., Fomin I.V., Ageev F.T., Begrambekova Y.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia.2018;58(6S):8–158 (In Russ.). DOI: 10.18087/cardio.2475.
2. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–1146. DOI: 10.1136/hrt.2003.025270.
3. Mitina E.V., Sturov N.V., Kobylyanu G.N., Mansur T.I., Rusanova E.I. Problems of diagnosis and treatment of chronic heart failure in outpatient practice. Trudny Patient. 2018;16(7):8–12 (In Russ.).
4. Garganeeva A.A., Kuzheleva E.A., Kuzmichkina M.A., Ryabov V.V., Mareev Y.V., Mareev V.Y. Characteristics and treatment of patients with heart failure admitted to a cardiology department in 2002 and 2016. Kardiologiia. 2018;58(12S):18–26 (In Russ.). DOI: 10.18087/cardio.2605.
5. Mesquita E.T., Demarchi A.V., dos Santos B.D., de Azevedo M.P.E., Badran P.M., de Almeida R.G.P. et al. Cardiovascular Continuum 25 years – The evolution of an etiopathophysiology model. Int. J. Cardiovasc. Sci. 2016;29(1):56–64. DOI: 10.5935/2359-4802.20160002.
6. Koshland D.E. Jr. The molecule of year. Science. 1992;258(5090):1861. DOI: 10.1126/science.1470903.
7. O’Rourke M.F., Safar M.E., Dzau V. The Cardiovascular Continuum extended: aging effects on the aorta and microvasculature. Vasc. Med. 2010;15(6):461–468. DOI: 10.1177/1358863X10382946.
8. Boitsov S.A., Pogosova N.V., Bubnova M.G., Drapkina O.M., Gavrilova N.E., Eganyun R.A. et al. Nacional rekommendations “Cardiovascular prevention 2017”. Moscow; 2017:288 (In Russ.).
9. Orlova I.A., Tkacheva O.N., Arutyunov G.P., Kotovskaya Y.V., Vasyuk Yu.A., Lopatin Y.M. et al. Features of diagnostics and treatment of chronic heart failure in elderly and senile patients. Expert opinion of the Society of Experts in Heart Failure, Russian Association of Gerontologists, and Eurasian Association of Therapists. Kardiologiia. 2018;58(12S):42–72 (In Russ.). DOI: 10.18087/cardio.2560.
10. Gilyarevsky S.R., Golshmid M.V., Kuzmina I.M., Bendeliani N.G. Anemia in patients with heart failure: Current state of the problem. Russian Sklifosovsky Journal “Emergency Medical Care”. 2019;8(1):68–73 (In Russ.). DOI: 10.23934/2223-9022-2019-8-1-68-73.
11. Kolegova I.I., Chernyavina A.I., Koziolova N.A. Characteristics of the course of chronic heart failure and the state of target organs in patients with cardiorenal syndrome. Russian Journal of Cardiology. 2018;(1):21– 26 (In Russ.). DOI: 10.15829/1560-4071-2018-1-21-26.
12. Tarlovskaya E.I., Mikhailova Y.V. Chronic heart failure and the frequency of taking nonsteroidal anti-infl ammatory drugs: A register-based study on the possible risks. Russian Journal of Cardiology. 2020;25(1):3677 (In Russ.). DOI: 10.15829/1560-4071-2020-1-3677.
13. Arutyunov A.G., Rylova A.K., Arutyunov G.P. Registry of hospitalized patients with decompensated circulation (“Pavlov’s hospital registr”). Report 2. Clinical signifi cance and prognostic role of some parameters determined during physical and instrumental examination of patients with decompensated circulation. Russian Heart Failure Journal. 2014;15(2):67– 75 (In Russ.). DOI: 10.18087/rhfj.2014.2.1934.
14. Vengerovsky A.I. Pharmacology. Course of lectures: textbook. Moscow: GEOTAR-Media; 2015:736 (In Russ.).
15. Mareev Y.V., Mareev V.Y. Characteristics and treatment of hospitalized patients with CHF. Kardiologiia. 2017;57(4S):19–30 (In Russ.). DOI: 10.18087/cardio.2433.
16. Wile D. Diuretics: a review. Ann. Clin. Biochem. 2012;49(5):419–431. DOI: 10.1258/acb.2011.011281.
17. Arutjunov G.P., Orlova Ja.A., Koziolova N.A., Arutyunov A.G., Dragunov D.O., Sokolova A.V. Fundamental and applied aspects of diuretic therapy. Moscow: Klinmed Consulting LLC; 2018:200 (In Russ.).
18. Tsutsui H., Ito H., Kitakaze M., Komuro I., Murohara T., Izumi T. et al. Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Effi cacy and Safety of Eplerenone in Japanese Patients With Chronic Heart Failure (J-EMPHASIS-HF). Circ. J. 2017;82(1):148–158. DOI: 10.1253/circj.CJ-17-0323.
19. Jacob M.S., Tang W.H. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF. Curr. Heart Fail. Rep. 2011;8(1):7–13. DOI: 10.1007/s11897-010-0046-0.
20. Gilyarevskiy S.R., Bendeliani N.G., Golshmid M.V., Kuzmina I.M. New Clinical Aspects of Eplerenone Use in Clinical Practice. Rational Pharmacotherapy in Cardiology. 2018;14(4):612-620 (In Russ.). DOI: 10.20996/1819-6446-2018-14-4-612-620.
21. Fudim M., O’Connor C.M., Mulder H., Coles A., Bhatt A.S., Ambrosy A.P. et al. Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. Am. Heart J. 2018;205:133–141. DOI: 10.1016/j.ahj.2018.06.017.
22. Dini F.L., Ghio S., Klersy C., Rossi A., Simioniuc A., Scelsi L. et al. Effects on survival of loop diuretic dosing in ambulatory patients with chronic heart failure using a propensity score analysis. Int. J. Clin. Pract. 2013;67(7):656–664. DOI: 10.1111/ijcp.12144.
23. Abdel-Qadir H.M., Tu J.V., Yun L., Austin P.C., Newton G.E., Lee D.S. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. American Нeart Journal. 2010;160(2):264–271:e1. DOI: 10.1016/j.ahj.2010.05.032.
24. Devroey D., van Casteren V. Symptoms and clinical sings associated with hospital admission and mortality for heart failure. Cent. Eur. J. Public Health. 2010;18(4):209–214.
25. DeVore A.D., Hasselblad V., Mentz R.J., O’Connor C.M., Armstrong P.W., McMurray J.J. et al. Loop diuretic dose adjustments after a hospitalization for heart failure: Insights from ASCEND-HF. Eur. J. Heart Fail. 2015;17(3):340–346. DOI: 10.1002/ejhf.235.
26. Kiernan M.S., Stevens S.R., Tang W.H.W., Butler J., Anstrom K.J., Birati E.Y. et al. Determinants of Diuretic Responsiveness and Associated Outcomes during Acute Heart Failure Hospitalization: An Analysis from the NHLBI Heart Failure Network Clinical Trials. J. Card. Fail. 2018;24(7):428–438. DOI: 10.1016/j.cardfail.2018.02.002.
27. Faris R.F., Flather M., Purceli H., Poole-Wilson P.A., Coats A.J.S. Diuretics for heart failure. Cochrane Database Syst. Rev. 2012;(2):CD003838. DOI: 10.1002/14651858.CD003838.pub3.
28. Cosín J., Díez J., TORIC investigators. Torasemide in chronic heart failure: Results of the TORIC Study. Eur. J. Heart Fail. 2002;4(4):507–513. DOI: 10.1016/s1388-9842(02)00122-8.
29. Rao V.S., Turner J.M., Griffi n M., Mahoney D., Asher J., Jeon S. et al. First in human experience with peritoneal direct sodium removal using a zero sodium solution: A new candidate therapy for volume overload. Circulation. 2020;14:1043–1053. DOI: 10.1161/CIRCULATIONAHA.119.043062.
30. Belenkov Yu.N., Shakarjants G.A. The place of torasemide in current therapy for chronic heart failure. Russian Heart Failure Journal. 2015;16(6):391–395 (In Russ.). DOI: 10.18087/rhfj.2015.6.2158.
31. Kostenko V.A., Sitnikova M.Yu., Skorodumova E.A., Fedorov A.N., Skorodumova E.G. New scale for assessment of prognosis of survival for two years after hospitalization because of acute decompensation of heart failure. Kardiologiia. 2017;57(6):33–39 (In Russ.).
32. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E. Jr., Drazner M.H. et al. 2013 ACCF/AH A guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 2013;62(16):147–239. DOI: 10.1016/j.jacc.2013.05.019.
33. Abraham W.T., Adamson P.B., Bourge R.C., Aaron M.F., Costanzo M.R., Stevenson L.W. et al. Wireless Pulmonary Artery Haemodynamic Monitoring in Chronic Heart Failure: A Randomised Controlled Trial. Lancet. 2011;377(9766):658–666. DOI: 10.1016/S0140-6736(11)60101-3.
34. Yu C.M., Wang L., Chau E., Chan R.H.-W., Kong S.L., Tang M.-O. et al. Intrathoracic impedance monitoring in patients with heart failure: Correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841–848. DOI: 10.1161/CIRCULATIONAHA.104.492207.
35. Mullens W., Damman K., Harjola V.-P., Mebazaa A., Brunner-La Rocca H.-P., Martens P. et al. The use of diuretics in heart failure with congestion – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2019;21(2):137–155. DOI: 10.1002/ejhf.1369.
36. Balakumar V., Murugan R., Sileanu F.E., Palevsky P., Clermont G., Kellum J.A. Both positive and negative fluid balance may be associated with reduced long-term survival in the critically Ill. Crit. Care Med. 2017;45(8):749–757. DOI: 10.1097/CCM.0000000000002372.
37. Khan A., Khan A.H., Adnan A.S., Sulaiman S.A.S., Ahmad N., Gan S.H. Evaluation of factors affecting time to achieve dry weight among hemodialysis patients using bioimpedance spectroscopy. Ir. J. Med. Sci. 2019;188(1):311–319. DOI: 10.1007/s11845-018-1813-2.
38. Gheorghiade M., Follath F., Ponikowski P., Barsuk J.H., Blair J.E.A., Cleland J.G. et al. Assessing and grading congestion in acute heart failure: A scientific statementfrom the Acute Heart Failure Committee of the Heart Failure Association ofthe European Society of Cardiology and endorsed by the European Society ofIntensive Care Medicine. Eur. J. Heart Fail. 2010;12(5):423–433. DOI: 10.1093/eurjhf/hfq045.
39. Kochav S.M., Flores R.J., Truby L.K., Topkara V.K. Prognostic impact of pulmonary artery pulsatility index (PAPi) in patients with advanced heart failure: Insights from the ESCAPE Trial. J. Card. Fail. 2018;24(7):453– 459. DOI: 10.1016/j.cardfail.2018.03.008.
40. Mareev Y.V., Gerasimova V.V., Goryunova T.V., Petrukhina A.A., Danielyan M.O., Kapanadze L.G. et al. Factors determining prognosis in chronic heart failure: The role of the width and morphology of the QRS complex. Russian Heart Failure Journal. 2012;13(5):255–266 (In Russ.).
41. Islam S. The art and science of using diuretics in the treatment of heart failure in diverse clinical settings. Adv. Exp. Med. Biol. 2018;1067:47–65. DOI: 10.1007/5584_2018_182.
42. Kobalava Z.D., Safarova A.F., Kokhan E.V., Islamova M.R. Lung ultrasound in optimizing management of patients with heart failure: current status and future prospects. Russian Journal of Cardiology. 2020;25(1):3666 (In Russ.). DOI: 10.15829/1560-4071-2020-1-3666.
43. Simon M.A., Schnatz R.G., Romeo J.D., Pacella J.J. Bedside ultrasound assessment of jugular venous compliance as a potential point‐of‐care method to predict acute decompensated heart failure 30‐day readmission. J. Am. Heart Assoc. 2018;7(15):008184. DOI: 10.1161/JAHA.117.008184.
44. Thibodeau J.T., Turer A.T., Gualano S.K., Ayers С.R., Velez-Martinez M., MishkinJ. D. et al. Characterization of a novel symptom of advanced heart failure: bendopnea. JACC Heart Fail. 2014;2(1):24–31. DOI: 10.1016/j.jchf.2013.07.009.
45. Dragunov D.O., Sokolova A.V., Arutjunov G.P., Gasanova A.D., Latyshev T.V. Тhe severity of bendopnea as a prognostic marker of decompensation of chronic heart failure. Clinical Pharmacology and Therapy. 2018;27(5):52–57 (In Russ.). DOI: 10.32756/0869-5490-2018-5-52-56.
46. Moiseev V.S., Martynov A.I., Mukhina N.A. Internal diseases. In 2 v. V. 2: textbook; 3rd.ed., add. Moscow: GEOTAR-Media; 2013:958 (In Russ.).
47. Formiga F., Chivite D., Manito N., Casas S., Llopis F., Pujol R. Hospitalization due to acute heart failure. Role of the precipitating factors. Int. J. Card. 2007;120(2):237–241. DOI: 10.1016/j.ijcard.2006.10.004.
48. FominI. V., Kraiem N., Polyakov D.S., Vinogradova N.G.,Valikulova F.Yu., Vaysberg A.R. et al. The notion of CHF course stability: Is it acceptable for Russian practice? Kardiologiia.2018;58(S3):55–63 (In Russ.).
49. Anker S.D., Ponikowski P., Varney S., Chua T.P., Clark A.L., WebbPeploe K.M. et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349(9058):1050–1053. DOI: 10.1016/ S0140-6736 (96)07015–8.
50. Androne A.S., Hryniewicz K., Hudaihed A., Mancini D., Lamanca J., Katz S.D. Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am. J. Cardiol. 2004;15;93(10):1254–1259. DOI: 10.1016/j.amjcard.2004.01.070.
51. Mamatov B.M., Klimenko A.S., Villevalde S.V., Kobalava Zh.D. Hydration status evaluation in patients with decompensated heart failure. Trudny Patient. 2016;14(10–11):6–9 (In Russ.).
52. Testani J.M., Chen J., McCauley B.D., Kimmel S.E., Shannon R.P. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation. 2010;122(3):265–272. DOI: 10.1161/CIRCULATIONAHA.109.933275.
53. Testani J.M., Brisco M.A., Chen J., McCauley B.D., Parikh C.R., Tang W.H.W. Timing of hemoconcentration during treatment of acute decompensated heart failure and subsequent survival: Importance of sustained decongestion. J. Am. Coll. Cardiol. 2013;62(6):516–524. DOI: 10.1016/j.jacc.2013.05.027.
54. Greene S.J., Gheorghiade M., Vaduganathan M., Ambrosy A.P., Subacius H., Mentz R.J. et al. Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: Insights from the EVEREST Trial. Eur. J. Heart Fail. 2013;15(12):1401–1411. DOI: 10.1093/eurjhf/hft110.
55. Androne A.S., Katz S.D., Lund L., LaManca J., Hudaihed A., Hryniewicz K. et al. Hemodilution is common in patients with advanced heart failure. Circulation. 2003;107:226–229. DOI: 10.1161/01.cir.0000052623.16194.80.
56. Kolyadich M.I. The ordinal scale of X-ray assessment of venous congestion in chronic heart failure. Kazan Medical Journal.2020;101(1):112–118 (In Russ.). DOI: 10.17816/KMJ2020-112.
57. Cardinale L., Priola A.M., Moretti F., Volpicelli G. Effectiveness of chest radiography, lung ultrasound, and thoracic computed tomography in the diagnosis of congestive heart failure. World J. Radiol. 2014;6:230–237. DOI: 10.4329/wjr.v6.i6.230.
58. Wooten W.M., Shaffer L.E., Hamilton L.A. Bedside Ultrasound versus Chest Radiography for Detection of Pulmonary Edema: A Prospective Cohort Study. J. Ultrasound Med. 2019;38(4):967–973. DOI: 10.1002/jum.14781.
59. Nijst P., Martens P., Dupont M., Tang W.H.W., Mullens W.. Intrarenal fl ow alterations during transition from euvolemia to intravascular volume expansion in heart failure patients. JACC Heart Failure. 2017;5(9):672–681. DOI: 10.1016/j.jchf.2017.05.006.
60. Saha N.M., Barbat J.J., Fedson S., Anderson A., Rich J.D., Spencer K.T. Outpatient use of focused cardiac ultrasound to assess the inferior vena cava in patients with heart failure. Am. J. Cardiol. 2015;116(8):1224– 1228. DOI: 10.1016/j.amjcard.2015.07.040.
61. Nagueh S.F., Smiseth O.A., Appleton C.P., Smiseth O.A., Appleton C.P., Byrd B.F. et al. Recommendations for the evaluation of left ventriculardiastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J. Am. Soc. Echocardiogr. 2016;29(4):277–314. DOI: 10.1016/j.echo.2016.01.011.
62. Beller G.A. Tests that may be overused or misused in cardiology: The Choosing Wisely®campaign. J. Nucl. Cardiol. 2012;(19):401–403. DOI: 10.1007/s12350-012-9569-y.
63. Mamatov B.M., Villevalde S.V., Klimenko A.S., Kobalava Z.D. Bioimpedance vector analysis for detecting subclinical congestion in patients with decompensated heart failure. Clinical Pharmacology and Therapy. 2016;25(5):45–49 (In Russ.).
64. Reljin N., Zimmer G., Malyuta Y., Shelley K., Mendelson Y., Blehar D.J. et al. Using support vector machines on photoplethysmographic signals to discriminate between hypovolemia and euvolemia. PLoS One. 2018;13(3):0195087. DOI: 10.1371/journal.pone.0195087.
65. Abraham W.T., Compton S., Haas G., Foreman B., Canby R.S., Fichel R. et al. Intrathoracic impedance vs daily weight monitoring for predicting worsening heart failure events: results of the Fluid Accumulation Status Trial (FAST). Congest. Heart Fail. 2011;17(2):51–55. DOI: 10.1111/j.1751-7133.2011.00220.x.
66. Shherbatjuk O.V., Tyrenko V.V., Belevitin A.B., Svistov A.S., Hubulava G.G. Brain natriuretic peptide–the genetic code of heart failure. Bulletin of the Russian Military Medical Academy. 2007;1(17):95–100 (In Russ.).
67. Richards A.M. N-terminal B-type natriuretic peptide in heart failure. Heart Fail. Clin. 2018;14(1):27–39. DOI: 10.1016/j.hfc.2017.08.004.
68. McKie P.M., Burnett J.C. Jr. NT-proBNP: The gold standard biomarker in heart failure. J. Am. Coll. Cardiol. 2016;68(22):2437–2439. DOI: 10.1016/j.jacc.2016.10.001.
69. Nikonova E.S., Suslova T.E., Ryabov V.V., Shurupov V.S. The cerebral sodium uretric peptide in patients with chronic cardiac insufficiency under decreased and preserved ejection fraction. Klinicheskaya Laboratornaya Diagnostika. 2013;8:21–23 (In Russ.).
70. Vaur L., Gueret P., Lievre M., Chabaud S., Passa P. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) Study. Diabetes Care. 2003;26(3):855–860. DOI: 10.2337/diacare.26.3.855.
71. Maeder M.T., Mueller C., Pfisterer M.E., Buser P.T., Brunner-la Rocca H.P. Use of B-type natriuretic peptide outside of the emergency department. Int. J. Cardiol. 2008;127(1):5–16. DOI: 10.1016/j.ijcard.2007.10.018.
72. Letsas K.P., Filippatos G.S., Pappas L.K., Mihas C.C., Markou V., Alexanian I.P. et al. Determinants of plasmaNT-pro-BNP levels in patients with atrial fibrillation and preserved left ventricular ejection fraction. Clin. Res. Cardiol. 2009;98:101–106. DOI: 10.1007/s00392-008-0728-8.
73. Stienen S., Salah K., Moons A.H., Bakx A.L., van Pol P., Kortz R.A.M. et al. NT-proBNP (N-terminal pro-B-type natriuretic peptide)-Guided Therapy in Acute Decompensated Heart Failure: PRIMA II Randomized Controlled Trial (Can NT-ProBNP-Guided Therapy During Hospital Admission for Acute Decompensated Heart Failure Reduce Mortality and Readmissions?). Circulation. 2018;137(16):1671–1683. DOI: 10.1161/CIRCULATIONAHA.117.029882.
74. Gayat E., Caillard A., Laribi S., Mueller C., Sadoune M., Seronde M.-F.. et al. Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. Int. J.Cardiol. 2015;199:241–247. DOI: 10.1016/j.ijcard.2015.07.039.
75. Nunez J., Llacer P., Bertomeu-Gonzalez V., Bosch M.J., Merlos P., García-Blas S. et al. Carbohydrate Antigen-125-guided Therapy in Acute Heart Failure: CHANCE-HF: А Randomized Study. JACC Heart Fail. 2016;4:833–843. DOI: 10.1016/j.jchf.2016.06.007.
76. Kremer D., Ter Maaten J.M., Voors A.A. Bio-adrenomedullin as a potential quick, reliable, and objective marker of congestion in heart failure. Eur. J. Heart Fail. 2018;20:1363–1365. DOI: 10.1002/ejhf.1245.
77. Turgay Ö.Y., Yıldırır A., Sade L.E., Hasırcı S.H., Kozan H., Özçalık E. et al. Is there a relationship between resistin levels and left ventricular end-diastolic pressure? Anatol. J. Cardiol. 2018;19(4):267–272.DOI: 10.14744/AnatolJCardiol.2018.66181.
Review
For citations:
Garganeeva A.A., Kuzheleva E.A., Mareev V.Yu. Euvolemia as a criterion of diuretic therapy efficacy in chronic heart failure: Literature review. Siberian Journal of Clinical and Experimental Medicine. 2020;35(2):13-25. (In Russ.) https://doi.org/10.29001/2073-8552-2020-35-2-13-25
Views:
2452
.png)
Email this article 